Louise Pedneault
Biographic Data
| ID | 10012133 |
|---|---|
| NAME | Louise Pedneault |
| GIVEN NAMES | Louise |
| FAMILY NAME | Pedneault |
| SIGNATURE | PEDNEAULT L |
| AFFILIATIONS | Pfizer (United States) |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 1997 |
| LATEST PUBLICATION YEAR | 2020 |
| H-INDEX | 0 |
Risk Factors for Primary Clostridium difficile Infection; Results From the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORC…
Background There are conflicting data on the risk factors for Clostridium difficile infection (CDI) in the literature. Aims To use two C. difficile infection (CDI) case-control study groups to compare risk factors in hospitalised patients with diarrhoea across different countries. Methods A multi-centre group of CDI cases/controls were identified by standardised testing from seven countries from the prior EUropean, multi-centre, prospective bi-an…
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
BACKGROUND: The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine. METHODS: A total of 1156 patients not previously treated with lamivudin…
No prominent works on this page.
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
BACKGROUND: The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine. METHODS: A total of 1156 patients not previously treated with lamivudin…
Risk Factors for Primary Clostridium difficile Infection; Results From the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORC…
Background There are conflicting data on the risk factors for Clostridium difficile infection (CDI) in the literature. Aims To use two C. difficile infection (CDI) case-control study groups to compare risk factors in hospitalised patients with diarrhoea across different countries. Methods A multi-centre group of CDI cases/controls were identified by standardised testing from seven countries from the prior EUropean, multi-centre, prospective bi-an…
Medicine (2 works) · Antibiotics (1 work) · Bacteria (1 work) · Biology (1 work) · Clostridium (1 work) · Clostridium difficile (1 work) · Clostridium difficile and Clostridium perfringens research (1 work) · Confidence interval (1 work) · Diarrhea (1 work) · Gastroenterology (1 work)